» Articles » PMID: 35505374

Specific Antibody Titer Decay in Neonates Prenatally Exposed to Toxoplasma Gondii and Their Mothers

Overview
Journal Ital J Pediatr
Publisher Biomed Central
Specialty Pediatrics
Date 2022 May 3
PMID 35505374
Authors
Affiliations
Soon will be listed here.
Abstract

Background: For infants exposed in utero to Toxoplasma gondii, current guidelines recommend monitoring the specific antibody titer until 12 months of age. In this study, we investigated the antibody titer decay in the mother-infant dyad.

Methods: This is a single center, population-based cohort study of neonates referred for prenatal exposure to Toxoplasma gondii from January 2014 to December 2020. All infants underwent clinical, laboratory, and instrumental investigation for at least 12 months.

Results: A total of 670 eligible neonates were referred to the Perinatal Infection Unit of the University Federico II of Naples. 636 (95%) completed the serological follow up until 12 months. Specific IgG antibodies negativization occurred in 628 (98.7%) within 5 months. At 9 and 12 months, all patients had negative IgG. An initial neonatal IgG antibody titer ≥ 200 IU/ml was associated with a longer time to negativization (184 [177.5;256] days when above threshold vs. 139.5 [101;179] days when below it; p < 0.001). Maternal IgG antibody titer ≥ 200 IU/ml at childbirth was also associated to delayed time to negativization in the infant (179 [163;184] days above the threshold vs 125 [96.8;178] days below it; p < 0.001). Specific antibody negativization was irreversible in all patients.

Conclusions: Lower anti-Toxoplasma antibody titers detected at birth in the mother-infant-dyad lead to an earlier and irreversible negativization. This information allows for customisation of the infant follow up program and avoids invasive and expensive tests.

Citing Articles

Congenital toxoplasmosis and audiological outcome: from a case series to a suggestion of patient-based schedule.

Salome S, Malesci R, Delle Cave V, Amitrano A, Gammella R, Fanelli F Front Pediatr. 2024; 11:1297208.

PMID: 38239593 PMC: 10794333. DOI: 10.3389/fped.2023.1297208.

References
1.
Pagliuca C, Pastore G, Scaglione E, Migliucci A, Maria Maruotti G, Cicatiello A . Genotyping of Toxoplasma gondii strain directly from human CSF samples of congenital toxoplasmosis clinical case. New Microbiol. 2017; 40(2):151-154. View

2.
Donadono V, Saccone G, Maria Maruotti G, Berghella V, Migliorini S, Esposito G . Incidence of toxoplasmosis in pregnancy in Campania: A population-based study on screening, treatment, and outcome. Eur J Obstet Gynecol Reprod Biol. 2019; 240:316-321. DOI: 10.1016/j.ejogrb.2019.07.033. View

3.
Capobiango J, Cabral Monica T, Ferreira F, Mitsuka-Bregano R, Navarro I, Garcia J . Evaluation of the Western blotting method for the diagnosis of congenital toxoplasmosis. J Pediatr (Rio J). 2016; 92(6):616-623. DOI: 10.1016/j.jped.2016.02.014. View

4.
Maldonado Y, Read J . Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. Pediatrics. 2017; 139(2). DOI: 10.1542/peds.2016-3860. View

5.
Mahmoudi S, Mamishi S, Suo X, Keshavarz H . Early detection of Toxoplasma gondii infection by using a interferon gamma release assay: A review. Exp Parasitol. 2016; 172:39-43. DOI: 10.1016/j.exppara.2016.12.008. View